Leukemia Therapeutics Market (2. Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid Leukemia, Pipeline Forecast & Market Forecast in G8 Countries, Market Research Report: Marketsand. Markets. Leukemia is the type of blood cancer and the ninth most common one in males. It accounts for almost 0. The leukemia market is segmented into four types; namely acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. The market was dominated by chronic myeloid leukemia in 2. However, in 2. 02. This report studies the market from 2. The growing population of leukemia is an impetus for the growth of the market. This market is expected to grow at a CAGR of 3.
North America was the major contributor to this market; accounting for 6. Gleevec was the major drug accounting for 5. Leukemia is still an area with high unmet need for early diagnosis and limited treatment options in this area. The report studies 1. Currently, there are about ten major drugs in pipeline for leukemia; which are expecting a market launch by 2. Talon Therapeutics Inc submitted new drug application to FDA for Marqibo in July 2. After chronic lymphocytic leukemia has been diagnosed, tests are done to find out how far the cancer has spread in the blood and bone marrow. Staging is the process. Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. Bone marrow is a soft, spongy substance within bones that produces. Quizartinib will be launched in the market in 2. Ambit Biosciences Inc (U. S.) on receiving fast track designation approval from the FDA in 2. The drug is expected to be priced at $2. Players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2. September 2. 01. 1. Pipeline drugs form a major growth strategy in the global leukemia therapeutics market accounting for 2. January 2. 00. 8 and September 2. Novartis International AG, Glaxo. Smith. Kline Pharmaceuticals Limited, Roche, Bristol- Myers Squibb, Genmab A/S, Celgene Corporation, and Biogen Idec rule the present market for leukemia drugs; whereas Ambit Bioscience & Pfizer are expected to capture major share of the market by 2. Scope of the report. This leukemia therapeutics market research report evaluates the leukemia drugs market with respect to the current and pipeline drugs and regimens. The report analyzes geography; forecasting revenue, and trends in each of the following submarkets: Chemotherapy regimens. CALGB 8. 81. 1 regimen. Linker regimen. AVD regimen Chemotherapy drugs. Campath/Mab. Campath. Cytarabine Pipeline drugs. GA1. 01 / RG7. 15. Marqibo The geographies covered under the report are North America. U. K. This report also provides market tables for covering the sub- segments and micro- markets. Additionally, it makes ways for company profiles that cover all the sub- segments. The report has been made by keeping past trends, current happenings and future forecasts in consideration. Customer Interested in this report also can view. TABLE OF CONTENTS 1 INTRODUCTION 1. KEY TAKE- AWAYS 1. REPORT DESCRIPTION 1. MARKETS COVERED 1. STAKEHOLDERS 1. RESEARCH METHODOLOGY 1. MARKET SIZE 1. KEY DATA POINTS TAKEN FROM SECONDARY SOURCES 1. ASSUMPTIONS MADE FOR THIS REPORT 2 EXECUTIVE SUMMARY 2. OVERVIEW OF THE MARKET 3 MARKET OVERVIEW 3. DEFINING LEUKEMIA 3. DIAGNOSIS 3. 1. Biopsy and bone marrow aspiration 3. Complete blood count (CBC) and differential 3. Philadelphia chromosome. LTD: TOTAL REVENUE & R& D EXPENSES, 2. LTD: PRODUCT PIPELINE TABLE 8. ERYTECH PHARMA: PRODUCT PIPELINE TABLE 8. GENMAB A/S: TOTAL REVENUE & R& D EXPENSES, 2. This type of cancer ia again sub- divided into acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), hairy cell leukemia (HCL), T- cell prolymphocytic leukemia (T- PLL), large granular lymphocytic leukemia, and adult T- cell leukemia. Amongst these, AML, ALL, CLL and CML are the most common types of leukemia. The risk of leukemia is closely associated with age. About 9. 0% of all leukemia. Incidence rate of leukemia is high in men and women over 6. Prevalence of chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia is very high in men and women between the ages of 7. Acute lymphocytic leukemia prevalence is high among one to four year old children and it is almost eight times more than the young adults aged between 2. Leukemia diagnosed population, 2. Thousands)Source: Globocan. Leukemia is expected to be more prominent in the developed world due to genetic and environmental factor, and radiation exposure is the primary cause of all the types of leukemia. The incidence and mortality rates for leukemia are higher in whites than in people of the other racial and ethnic groups due to genetic factors. Generally, men are more likely to develop leukemia than women. It is estimated that males accounted for more than 5.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2017
Categories |